What is the role of obinutuzumab in follicular lymphoma (FL) treatment?

Updated: Jan 16, 2019
  • Author: Francisco J Hernandez-Ilizaliturri, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print
Answer

Answer

Obinutuzumab

Obinutuzumab is indicated for FL in patients who are refractory to, or relapsed after, a rituximab-containing regimen. [20]

Obinutuzumab is administered with bendamustine for six 28-day cycles:

  • Cycle 1: obinutuzumab 1000 mg IV on days 1, 8, and 15 plus bendamustine 90 mg/m 2/day IV on days 1 and 2
  • Cycles 2-6: obinutuzumab 1000 mg IV on day 1 plus bendamustine 90 mg/m 2/day IV on days 1 and 2
  • Monotherapy:  Patients who achieve stable disease, complete response, or partial response to the first six cycles should continue on obinutuzumab 1000 mg IV every 2 months for 2 years

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!